BR112022010952A2 - Nanosferas de plga carregadas de proteína - Google Patents
Nanosferas de plga carregadas de proteínaInfo
- Publication number
- BR112022010952A2 BR112022010952A2 BR112022010952A BR112022010952A BR112022010952A2 BR 112022010952 A2 BR112022010952 A2 BR 112022010952A2 BR 112022010952 A BR112022010952 A BR 112022010952A BR 112022010952 A BR112022010952 A BR 112022010952A BR 112022010952 A2 BR112022010952 A2 BR 112022010952A2
- Authority
- BR
- Brazil
- Prior art keywords
- drug delivery
- delivery vector
- therapeutic substance
- protein
- loaded plga
- Prior art date
Links
- 239000002077 nanosphere Substances 0.000 title abstract 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 title abstract 2
- 238000012377 drug delivery Methods 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 4
- 239000000126 substance Substances 0.000 abstract 4
- 230000001225 therapeutic effect Effects 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 238000012286 ELISA Assay Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000010828 elution Methods 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944191P | 2019-12-05 | 2019-12-05 | |
| PCT/US2020/063314 WO2021113638A1 (en) | 2019-12-05 | 2020-12-04 | Protein-loaded plga nanospheres |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022010952A2 true BR112022010952A2 (pt) | 2022-09-06 |
Family
ID=76221229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022010952A BR112022010952A2 (pt) | 2019-12-05 | 2020-12-04 | Nanosferas de plga carregadas de proteína |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US12214046B2 (https=) |
| EP (1) | EP4072536A4 (https=) |
| JP (1) | JP7818514B2 (https=) |
| KR (1) | KR20220143811A (https=) |
| CN (1) | CN115335041A (https=) |
| AU (1) | AU2020396557A1 (https=) |
| BR (1) | BR112022010952A2 (https=) |
| CA (1) | CA3160922A1 (https=) |
| IL (1) | IL293607A (https=) |
| MX (1) | MX2022006824A (https=) |
| WO (1) | WO2021113638A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021113638A1 (en) | 2019-12-05 | 2021-06-10 | West Virginia University | Protein-loaded plga nanospheres |
| CN116855571B (zh) * | 2023-06-26 | 2025-03-21 | 中国农业大学 | Plga纳米球病毒示踪剂及其制备方法与应用 |
| KR20250069077A (ko) * | 2023-11-10 | 2025-05-19 | 아주대학교산학협력단 | 패티케이션 기술을 적용한 쿠에티아핀-지방산 접합체 나노입자 및 이의 장기 지속형 주사제 용도 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6406719B1 (en) | 1998-05-13 | 2002-06-18 | Microbiological Research Authority | Encapsulation of bioactive agents |
| FR2793684B1 (fr) | 1999-05-17 | 2001-08-10 | Ethypharm Lab Prod Ethiques | Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant |
| US20040003402A1 (en) | 2002-06-27 | 2004-01-01 | Digeo, Inc. | Method and apparatus for automatic ticker generation based on implicit or explicit profiling |
| US6974862B2 (en) | 2003-06-20 | 2005-12-13 | Kensey Nash Corporation | High density fibrous polymers suitable for implant |
| US20070026005A1 (en) * | 2003-09-09 | 2007-02-01 | Sung Young C | Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere |
| KR100622996B1 (ko) * | 2005-03-03 | 2006-09-14 | 한국과학기술원 | 약물이 봉입된 비다공성 고분자 미립 담체 및 이의 제조방법 |
| WO2007074604A1 (ja) | 2005-12-26 | 2007-07-05 | Ltt Bio-Pharma Co., Ltd. | 水溶性非ペプチド性低分子薬物含有ナノ粒子 |
| US10265407B2 (en) | 2007-02-15 | 2019-04-23 | Yale University | Modular nanodevices for smart adaptable vaccines |
| EP2251006B1 (en) | 2008-02-22 | 2017-07-19 | Toray Industries, Inc. | Microparticles and pharmaceutical compositions thereof |
| US9972047B1 (en) | 2008-04-18 | 2018-05-15 | Capital One Services, Llc | Systems and methods for performing a purchase transaction using rewards points |
| US20090281888A1 (en) | 2008-05-09 | 2009-11-12 | Li-Cheng Richard Zai | Method And Apparatus For Establishing Time-Based Loyalty Relationship |
| EA020954B1 (ru) | 2008-06-16 | 2015-03-31 | Бинд Терапьютикс, Инк. | Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака |
| RU2011126338A (ru) * | 2008-11-28 | 2013-01-10 | Эбботт Лэборетриз | Стабильные композиции антител и способы их стабилизации |
| WO2011063177A1 (en) | 2009-11-20 | 2011-05-26 | Mobisave Corporation | System and method of electronically verifying required proof-of-performance to secure promotional rewards |
| WO2011119262A1 (en) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc. | Methods and systems for generating nanoparticles |
| US9782342B2 (en) * | 2010-10-11 | 2017-10-10 | Wichita State University | Composite magnetic nanoparticle drug delivery system |
| BR112014006596A2 (pt) * | 2011-09-21 | 2017-03-28 | Yissum Res Dev Co | nanopartícula que encapsula uma pluralidade de nanocarreadores, composição, uso de uma nanopartícula, kit, sistema de entrega, processo para obter uma nanopartícula, e, processo de nanoaspersão para obter as nanopartículas |
| US9562015B2 (en) * | 2011-11-17 | 2017-02-07 | The Regents Of The University Of Colorado, A Body | Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations |
| CA2869748C (en) * | 2012-04-12 | 2017-10-24 | Yale University | Vehicles for controlled delivery of different pharmaceutical agents |
| WO2013166487A1 (en) | 2012-05-04 | 2013-11-07 | Yale University | Highly penetrative nanocarriers for treatment of cns disease |
| US9724304B2 (en) | 2012-06-14 | 2017-08-08 | Temple University—Of the Commonwealth System of Higher Education | Nanospheres for therapeutic agent delivery |
| US9308172B2 (en) | 2012-10-26 | 2016-04-12 | Board Of Trustees Of Michigan State University | Device and method for encapsulation of hydrophilic materials |
| CA2929277C (en) * | 2013-11-01 | 2018-01-16 | Yale University | Delivery vehicles comprising il-2 and losartan |
| WO2016061201A1 (en) * | 2014-10-14 | 2016-04-21 | The Brigham And Women's Hospital, Inc. | Nanoparticles and methods of use |
| CN104622795B (zh) * | 2015-01-28 | 2017-12-08 | 杭州市萧山区中医院 | 一种多细胞因子序贯缓释微球‑水凝胶复合系统及其制备方法 |
| CN108064176A (zh) | 2015-04-22 | 2018-05-22 | 库瑞瓦格股份公司 | 用于治疗肿瘤疾病的含有rna的组合物 |
| US20170056327A1 (en) * | 2015-08-25 | 2017-03-02 | The Methodist Hospital | Micro/nano composite drug delivery formulations and uses thereof |
| WO2019162951A1 (en) * | 2018-02-26 | 2019-08-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Drug delivery systems |
| EP3987054A4 (en) | 2019-06-18 | 2023-06-14 | Biomeme Incorporated | SAMPLE ANALYSIS SYSTEMS |
| WO2021113638A1 (en) | 2019-12-05 | 2021-06-10 | West Virginia University | Protein-loaded plga nanospheres |
-
2020
- 2020-12-04 WO PCT/US2020/063314 patent/WO2021113638A1/en not_active Ceased
- 2020-12-04 CA CA3160922A patent/CA3160922A1/en active Pending
- 2020-12-04 JP JP2022534255A patent/JP7818514B2/ja active Active
- 2020-12-04 AU AU2020396557A patent/AU2020396557A1/en active Pending
- 2020-12-04 BR BR112022010952A patent/BR112022010952A2/pt unknown
- 2020-12-04 MX MX2022006824A patent/MX2022006824A/es unknown
- 2020-12-04 IL IL293607A patent/IL293607A/en unknown
- 2020-12-04 EP EP20896361.1A patent/EP4072536A4/en active Pending
- 2020-12-04 CN CN202080095857.XA patent/CN115335041A/zh active Pending
- 2020-12-04 KR KR1020227022928A patent/KR20220143811A/ko active Pending
-
2022
- 2022-06-02 US US17/830,615 patent/US12214046B2/en active Active
-
2024
- 2024-11-13 US US18/946,447 patent/US20250064949A1/en active Pending
- 2024-11-19 US US18/952,404 patent/US20250073343A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023504282A (ja) | 2023-02-02 |
| US20250064949A1 (en) | 2025-02-27 |
| CN115335041A (zh) | 2022-11-11 |
| US20250073343A1 (en) | 2025-03-06 |
| EP4072536A4 (en) | 2025-01-15 |
| US20230070180A1 (en) | 2023-03-09 |
| IL293607A (en) | 2022-08-01 |
| AU2020396557A1 (en) | 2022-06-23 |
| EP4072536A1 (en) | 2022-10-19 |
| CA3160922A1 (en) | 2021-06-10 |
| WO2021113638A1 (en) | 2021-06-10 |
| MX2022006824A (es) | 2022-09-19 |
| JP7818514B2 (ja) | 2026-02-20 |
| KR20220143811A (ko) | 2022-10-25 |
| US12214046B2 (en) | 2025-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022010952A2 (pt) | Nanosferas de plga carregadas de proteína | |
| Zhou et al. | The effect of quercetin on the osteogenesic differentiation and angiogenic factor expression of bone marrow-derived mesenchymal stem cells | |
| Yin et al. | The methylmercury‐l‐cysteine conjugate is a substrate for the L‐type large neutral amino acid transporter | |
| Narita et al. | Multiple primary cilia modulate the fluid transcytosis in choroid plexus epithelium | |
| Kim et al. | Combined therapeutic application of mTOR inhibitor and vitamin D3 for inflammatory bone destruction of rheumatoid arthritis | |
| Abu-Eid et al. | Targeting the PI3K/Akt/mTOR pathway: A therapeutic strategy in COVID-19 patients | |
| Kulkarni et al. | Phenylbutyrate induces cathelicidin expression via the vitamin D receptor: Linkage to inflammatory and growth factor cytokines pathways | |
| JP6896050B2 (ja) | ＴＡＴｋ−ＣＤＫＬ５融合タンパク質、組成物、製剤、及びそれらの使用 | |
| MX2021005482A (es) | Lípidos de 2,5-dioxopiperazina con porciones éster, tioéster, disulfuro y anhidrido intercaladas. | |
| BR112012027055A8 (pt) | agente estabilizante para proteínas farmacêuticas. | |
| JP2016513075A5 (https=) | ||
| BR112012018951A8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
| BR112016029713A8 (pt) | uso de uma carboximetilcelulose reticulada e uso de um agente gelificante | |
| BR112018077021A2 (pt) | terapias de combinação | |
| BR112016015660A2 (pt) | formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg) | |
| Lu et al. | PTH/PTHrP in controlled release hydrogel enhances orthodontic tooth movement by regulating periodontal bone remodaling | |
| Gotoh et al. | Effects of repeated treatment with a delta opioid receptor agonist KNT-127 on hyperemotionality in olfactory-bulbectomized rats | |
| Landoni et al. | Remote ischemic preconditioning and cardiac surgery | |
| Zhao et al. | RETRACTED ARTICLE: Adiponectin administration alleviates DSS-induced colonic inflammation in Caco-2 cells and mice | |
| Khattab et al. | The BMP2 antagonist inhibitor L51P enhances the osteogenic potential of BMP2 by simultaneous and delayed synergism | |
| BR112022026999A2 (pt) | Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas | |
| BR112022016010A2 (pt) | Formulações de anticorpos anti-tslp humanos e métodos de tratamento de doenças inflamatórias | |
| Liu et al. | TSC-36/FRP inhibits vascular smooth muscle cell proliferation and migration | |
| BR112018071972A2 (pt) | métodos para tratamento ou prevenção de uma doença ou distúrbio de fígado, para tratamento de câncer de fígado e para tratamento de inflamação no fígado, trato biliar ou pâncreas de um animal, alfa-defensina e/ou ss-defensina de mamífero e/ou uma catelicidina e/ou um análogo de glp-1, e, uso dos mesmos. | |
| US9228005B2 (en) | Myonectin (CTRP15), compositions comprising same, and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |